Moderna Inc (NAS:MRNA)
$ 43.39 1.34 (3.19%) Market Cap: 16.70 Bil Enterprise Value: 10.67 Bil PE Ratio: 0 PB Ratio: 1.40 GF Score: 66/100

Moderna Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 14, 2019 / 04:20PM GMT
Release Date Price: $23.59 (-3.44%)
Ying Huang
BofA Merrill Lynch, Research Division - Director in Equity Research

All right. Great. So let's get started. My name is Ying Huang, and I'm a senior analyst covering large cap healthcare here at BofA Merrill Lynch. Welcome to the first day of our conference in Las Vegas. Our next presenting company is Moderna Therapeutics. Moderna actually went public recently, and it's actually one of the largest IPOs in history of [tal tech]. So we're pleased to have Lorence Kim, the Chief Financial Officer of Moderna; and also Dr. Tal Zaks, the Chief Medical Officer from Moderna with us.

Questions & Answers

Ying Huang
BofA Merrill Lynch, Research Division - Director in Equity Research

So with that, let me just kick off maybe by asking Lorence a high-level question. That is, there are many different approaches for RNA therapeutics in the market and also under -- I mean in the stock market, not in commercial market yet. So can you talk about what's the unique approach about the messenger RNA Moderna is pioneering in the development field? And how do you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot